Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

The response rate was higher in those with a KRAS mutation at 44%, compared to 17% in KRAS wild-type patients.

The published data showed that the combination of avutometinib plus defactinib demonstrated a confirmed overall response rate of 31% in all patients with recurrent low-grade serous ovarian cancer ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...

Find the latest Verastem, Inc. (VSTM) stock quote, history, news and other vital information to help you with your stock trading and investing.

“Rob and Seth are great additions to the Board of Directors. I look forward to working with them, and John in his new role, to create value for Harvard Bioscience’s shareholders. On behalf of the ...

Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 '25 revenue anticipated to be $20.4 million and Company reiterates pr ...

Ovarian Cancer Drugs Market grows as FDA, EMA fast-track advanced-stage therapies, boosting global approvals and innovation. Anurag Tiwari Orion Market Research Pvt Ltd + +91 91798 28694 email us here ...

Briefing documents were disclosed relating to the meeting of the U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC), which will convene July 17 on the matter of London-based GSK plc’s Blenrep ...